Ability to acquire drug resistance arises early during the tumorigenesis process.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  2007-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-2574PMID 17283147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting multidrug resistance in cancer

  2006cited by this paper
• Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN‐mutated prostate cancer cells

  2005cited by this paper
• What has senescence got to do with cancer?

  2005cited by this paper
• Caspase-2 function in response to DNA damage.

  2005cited by this paper
• Understanding transformation: progress and gaps.

  2005cited by this paper
• P-glycoprotein expression in soft-tissue sarcomas

  2005cited by this paper
• ATP‐binding cassette superfamily transporter gene expression in human soft tissue sarcomas

  2005cited by this paper
• Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• Sall1, a causative gene for Townes-Brocks syndrome, enhances the canonical Wnt signaling by localizing to heterochromatin.

  2004cited by this paper
• Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1

  2004cited by this paper
• DNA damage-induced apoptosis

  2004cited by this paper
• Functional Genetic Screen for Genes Involved in Senescence: Role of Tid1, a Homologue of the Drosophila Tumor Suppressor l(2)tid, in Senescence and Cell Survival

  2004cited by this paper
• Activation of the MDR1 Upstream Promoter in Breast Carcinoma as a Surrogate for Metastatic Invasion

  2004cited by this paper
• Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.

  2004influential reference
• To die or not to die: how does p53 decide?

  2004cited by this paper
• Multidrug transporter activity in lymphocytes

  2004influential reference
• Prognostic value of ERBB family mRNA expression in breast carcinomas

  2003cited by this paper
• P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation*

  2003cited by this paper
• The role of p53 in chemosensitivity and radiosensitivity

  2003cited by this paper
• p53 family members and chemoresistance in cancer: what we know and what we need to know.

  2003cited by this paper
• Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.

  2003cited by this paper
• Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.

  2003cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Rules for making human tumor cells.

  2002cited by this paper
• Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

  2001cited by this paper
• Derivation of human tumor cells in vitro without widespread genomic instability.

  2001cited by this paper
• Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic.

  2001cited by this paper
• Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells.

  2001cited by this paper
• Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation.

  2000cited by this paper
• Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis.

  2000cited by this paper
• Creation of human tumour cells with defined genetic elements

  1999influential reference
• Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.

  1999cited by this paper
• Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)

  1997cited by this paper
• Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

  1997cited by this paper
• Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

  1996cited by this paper
• Human cytogenetics : essential data

  1994cited by this paper
• Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations

  1993cited by this paper
• Thymocyte apoptosis induced by p53-dependent and independent pathways

  1993cited by this paper
• p53 is required for radiation-induced apoptosis in mouse thymocytes

  1993cited by this paper

• Role of Oxidative Stress in the Occurrence, Development, and Treatment of Breast Cancer

  2025cites this paper
• Plasmablast-like lymphoma cells as a distinct subpopulation confers multidrug resistance in PCNSL.

  2025cites this paper
• Nano-Encapsulated Taro Lectin Can Cross an in vitro Blood-Brain Barrier, Induce Apoptosis and Autophagy and Inhibit the Migration of Human U-87 MG Glioblastoma Cells

  2025cites this paper
• Unravelling Alpha-Mangostin as a Promising Anticancer Agent: An Overview of Therapeutic Effects, Molecular Mechanisms, and Strategies to Improve Treatment Outcomes

  2025cites this paper
• Harnessing the role of rubiadin in cancer: Current scenario and future perspectives.

  2025cites this paper
• A novel USP4 inhibitor that suppresses colorectal cancer stemness by promoting β-catenin and Twist1 degradation

  2025cites this paper
• Role of Phytoconstituents in Cancer Treatment: A Review.

  2024cites this paper
• Tumor Microenvironment Modulation by Cancer-Derived Extracellular Vesicles

  2024cites this paper
• Pachymic acid promotes ferroptosis and inhibits gastric cancer progression by suppressing the PDGFRB-mediated PI3K/Akt pathway

  2024cites this paper
• Natural Products as Anticancer Agents: Current Status and Future Perspectives

  2022cites this paper
• Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment.

  2022cites this paper
• Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer.

  2022cites this paper
• Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines

  2021cites this paper
• MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells.

  2021cites this paper
• Phenotypic Characterization of Immortalized Chondrocytes from a Desbuquois Dysplasia Type 1 Mouse Model: A Tool for Studying Defects in Glycosaminoglycan Biosynthesis

  2021cites this paper
• Gene microarray expression profile analysis of differentially expressed genes of potential alternative pathways in non–small cell lung cancer: In search of biomarkers

  2020cites this paper
• Visualizing the cell ferroptosis via a novel polysiloxane-based fluorescent schiff base

  2019cites this paper
• A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma

  2019cites this paper
• Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses.

  2018cites this paper
• Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis

  2018cites this paper
• Telomerase and drug resistance in cancer

  2017cites this paper
• Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?

  2017cites this paper
• Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer

  2017cites this paper
• NOTCH1 mediates a switch between two distinct secretomes during senescence

  2016cites this paper
• Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.

  2016cites this paper
• Prenatal versus Postnatal Screening for Familial Retinoblastoma.

  2016cites this paper
• Natural Polyphenols in Cancer Chemoresistance

  2016cites this paper
• MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.

  2016cites this paper
• Isoalantolactone induces autophagic cell death in SKOV₃ human ovarian carcinoma cells via upregulation of PEA-15.

  2016cites this paper
• Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.

  2016cites this paper
• Data driven approaches to identify determinants of heart diseases and cancer resistance

  2016cites this paper
• Resistance in Breast Cancer Chemotherapy: Patterns and Mechanisms

  2016cites this paper
• Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance.

  2015cites this paper
• miR-106 b ~ 25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP 300

  2015cites this paper
• Differential Gene Regulation in Fibroblasts in Co-culture with Keratinocytes and Head and Neck SCC Cells.

  2015cites this paper
• Lipid-albumin nanoassemblies co-loaded with borneol and paclitaxel for intracellular drug delivery to C6 glioma cells with P-gp inhibition and its tumor targeting

  2015cites this paper
• Spiramine derivatives induce apoptosis of Bax(-/-)/Bak(-/-) cell and cancer cells.

  2014cites this paper
• Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo.

  2014cites this paper
• Identification and characterization of downstream effector protein(s) regulated by p53 and pRb

  2014influential citation
• P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.

  2013cites this paper
• Telomerase as a useful target in cancer fighting—the breast cancer case

  2013cites this paper
• Multidrug resistance associated with glutathione

  2013cites this paper
• The miR-106b∼25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300

  2013influential citation
• Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.

  2013cites this paper
• Different strategies to overcome multidrug resistance in cancer.

  2013cites this paper
• Application of stem cells in targeted therapy of breast cancer: a systematic review.

  2013cites this paper
• The Multidrug Resistant Modulator HZ08 Reverses Multidrug Resistance via P-glycoprotein Inhibition and Apoptosis Sensitization in Human Epidermoid Carcinoma Cell Line KBv200

  2012cites this paper
• The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells.

  2012cites this paper
• Microarray Analysis and Biochemical Correlations of Oxidative Stress Responsive Genes in Retinoblastoma

  2012cites this paper
• Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes.

  2012cites this paper
• Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.

  2011cites this paper
• Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer

  2011cites this paper
• Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.

  2011cites this paper
• Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

  2011cites this paper
• Nanoparticles: A Promising Modality in the Treatment of Sarcomas

  2011cites this paper
• Biodistribution and Pharmacokinetic Analysis of Combination Lonidamine and Paclitaxel Delivery in an Orthotopic Animal Model of Multi-drug Resistant Breast Cancer Using EGFR-Targeted Polymeric Nanoparticles

  2011cites this paper
• Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning

  2011cites this paper
• Cyclin G–Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking

  2010cites this paper
• Tumor hypoxia, the Warburg effect, and multidrug resistance: Modulation of hypoxia induced MDR using EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine therapy

  2010cites this paper
• Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone

  2010cites this paper
• Implications of Anthracycline‐Resistant and Taxane‐Resistant Metastatic Breast Cancer and New Therapeutic Options

  2010cites this paper
• Are RAS mutations predictive markers of resistance to standard chemotherapy?

  2009cites this paper
• Mechanisms of tumor resistance to EGFR-targeted therapies

  2009cites this paper
• Resistance to chemotherapy: new treatments and novel insights into an old problem

  2008influential citation
• Multi-functional nanocarriers to overcome tumor drug resistance.

  2008influential citation
• Chinese Herbs of Shenghe Powder Reverse Multidrug Resistance of Gastric Carcinoma SGC-7901

  2007cites this paper
• Chinese herbs of Shenghe Powder reverse multidrug resistance of gastric carcinoma SGC-7901.

  2007cites this paper
• How cancer drugs are discovered and developed

  year unknowncites this paper